Soligenix

Soligenix FCF Growth

The Year-over-Year Free Cash Flow Growth of Soligenix (SNGX) as of Oct 16, 2026 is -22.24 %. In the previous year, Year-over-Year Free Cash Flow Growth was 2.33 % — a change of -1,054.35% (lower).

FCF Growth

-22.24 %

YoY

-1,054.35%

Last updated:

Year-over-Year Free Cash Flow Growth of Soligenix is 2025 -22.24 % . Year-over-Year Free Cash Flow Growth of Soligenix was 2024 2.33 % . It decreases by -1,054.35% lower compared to the previous year.

The Soligenix FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2018
-10.86 USD
Jan 1, 2019
-4.05 USD
Jan 1, 2020
-52.01 USD
Jan 1, 2021
-2.53 USD
Jan 1, 2022
-7.75 USD
Jan 1, 2023
32.05 USD
Jan 1, 2024
2.33 USD
Jan 1, 2025
-22.24 USD
The Soligenix FCF Growth history
YEARFCF GrowthYoY
-22.24 %-1,054.35%
2.33 %-92.73%
32.05 %-513.55%
-7.75 %+206.46%
-2.53 %-95.14%
-52.01 %+1,185.48%
-4.05 %-62.73%
-10.86 %-64.99%
-31.01 %-500.46%
7.74 %-106.74%
-114.82 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Soligenix Stock analysis

What does Soligenix do? Soligenix Inc, trading under the ticker SNGX, is a biotechnology company based in Princeton, New Jersey. The company has an IPO date of April 4, 1994, and currently employs 13 people. Soligenix operates in the health care sector, specifically within biotechnology. The company focuses on developing and commercializing treatments for rare diseases. Its business segments include Specialized BioTherapeutics and Public Health Solutions. Under Specialized BioTherapeutics, Soligenix is developing SGX301, a photodynamic therapy using topical synthetic hypericin activated by visible light for cutaneous T-cell lymphoma (CTCL). The Public Health Solutions segment encompasses development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate targeting antibiotic-resistant and emerging infectious diseases. The company also references CTCL as an innate defense regulator technology, though this appears to be a misstatement as CTCL is a disease, not a technology. Soligenix's website is https://www.soligenix.com/. Soligenix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Soligenix stock

Year-over-Year Free Cash Flow Growth of Soligenix is -22.24 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Soligenix since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Soligenix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Soligenix

All Key Metrics — Soligenix